USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc.

Data from the DeLLphi-304 trial “clearly support tarlatamab as a preferable therapy” for SCLC in the second-line setting, said Charles M. Rudin, MD, PhD.

In a significant showcase for investors, BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will announce major advancements to its industry-leading oncology ...

Georgia Gardiner, 28, mother to two-year-old Arlo, from Leeds in West Yorkshire, has been told she has two years to live ...

Cambridge: AstraZeneca has announced that Datroway (datopotamab deruxtecan or Dato-DXd) has received accelerated approval ...

Australians with a high risk of developing lung cancer can be screened for the disease free of charge through Medicare.This is ...